Gilead Sciences can now start going to work on commercializing the drug it paid $11 billion to get a couple years ago.
The Foster City, CA-based biotech company (NASDAQ: GILD)... Read more »
Why would anybody want to build a biotech company for the long term?
Nobody should cry a river for well-paid biotech executives, but there are easier ways to make a living.... Read more »
Like its name suggests, 5AM Venture Management likes to place its bets early in the life of a company. Now it has reloaded with another $250 million to put to work... Read more »
Scientists have tried for decades to coax the body’s immune system to hunt down and kill cancer cells, much in the same way it fights viruses and bacteria. The idea has... Read more »
Seattle-based Blaze Bioscience, the company making “tumor paint” so surgeons can tell the difference between healthy tissue and tumors that should be removed, just raised another $9 million to see... Read more »
San Francisco-based Burrill & Company looked like it had beaten the odds a little more than a year ago during a tough time for biotech venture capital firms. Burrill said in... Read more »
Theraclone Sciences tried to merge with PharmAthene for a couple of months, but the deal is off.
Annapolis, MD-based PharmAthene (NYSE MKT: PIP) chose to pull the plug on a... Read more »
Lots of biotech companies today say they want to be great for a long, long time. But which of today’s companies are actually doing it? Which ones are truly visionary, and... Read more »
Yesterday, I ran the first installment of an interview with Trevor Mundel, the president of global health at the Seattle-based Bill & Melinda Gates Foundation. He talked about his personal... Read more »
Merck threw out some assets a few years ago when it did its mega-merger with Schering-Plough. Now we can see that some savvy investors think it might have tossed aside a... Read more »
Bill Gates can summon the CEOs of every major global pharmaceutical company, and get them thinking and talking about things that won’t help them make more money. Pharma and biotech... Read more »
David Botstein, one of the more prominent geneticists of his generation, was winding down his academic lab earlier this year.
His term as director of the Lewis-Sigler Institute for Integrative... Read more »
We live every day with trillions of bacterial neighbors that do all sorts of mysterious things in our guts, good and bad. The broadening scientific understanding of the “microbiome,”... Read more »
Many of today’s biotech companies don’t aspire to be companies at all. They’re more like temporary “virtual” projects, with skeleton crews of contractors who come together for a spell and then... Read more »
Moderna Therapeutics doesn’t need cash to keep the doors open, like many biotech startups. It just went out and raised a ton of dough, anyway.
The Cambridge, MA-based biotech startup, which... Read more »
[Updated: 5:55 pm PT] Google’s new high-profile anti-aging startup, Calico, stirred up plenty of intrigue this fall when it made the cover of Time magazine. Now it has... Read more »
What does it take to build a life sciences company that can stand on its own two feet for a long, long time?
There’s no single answer to that question. Lots... Read more »
[Updated: 12:45 pm PT 12/13/13] We’ve heard a lot this year about the IPO boom for biotech companies. Even after a few high-profile blowups (Ariad, Sarepta),... Read more »
Hal Barron, when he was a young physician, joined Genentech as a clinical scientist back in 1996. It was the year of Genentech’s 20th anniversary.
It sounds hard to believe... Read more »
[Updated: 11:15 am PT] Investors have been projecting billions in future sales for a new blood cancer treatment from Sunnyvale, CA-based Pharmacyclics (NASDAQ: PCYC) and Johnson & Johnson,... Read more »